ZimVie Inc. announced on July 21, 2025, its entry into a definitive agreement to be acquired by an affiliate of ARCHIMED, an investment firm focused exclusively on healthcare industries. Under the terms, ZimVie stockholders will receive $19.00 in cash for each share of common stock.
This transaction corresponds to an enterprise value of approximately $730 million. The per share price represents a premium of 99% to ZimVie's 90-day volume-weighted average price of $9.57 per share.
The Board of Directors of ZimVie unanimously approved the transaction, which is expected to close by year-end 2025, subject to stockholder and regulatory approvals. Upon completion, ZimVie will become a privately held company, and its shares will no longer be listed on the NASDAQ stock exchange. The agreement also includes a 40-day 'go-shop' period through August 29, 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.